DOCSLIB.ORG

Adrenal Steroid Levels in Castrated Men with Prostatic Carcinoma Treated with Aminoglutethimide Plus Hydrocortisone1 Frederick R

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adrenal Steroid Levels in Castrated Men with Prostatic Carcinoma Treated with Aminoglutethimide Plus Hydrocortisone1 Frederick R [CANCER RESEARCH 47, 4736-4739, September 1, 1987) Adrenal Steroid Levels in Castrated Men with Prostatic Carcinoma Treated with Aminoglutethimide plus Hydrocortisone1 Frederick R. Minianti, ' E. David Crawford, Willi Kreis, Yvan Levasseur, and The Aminoglutethimide Study Group Section of Hematology and Oncology, Tucson VA Medical Center, Tucson 85723 and University of Arizona School of Medicine, Tucson 85724 [F. R. A.J Arizona; Division of Urology, University of Colorado Health Sciences Center, Denver, Colorado 80262 [D. C.J;Northshore University Hospital, Cornell University Medical Center, Manhasset, New York 11030 [W. K.J; and Ciba-Geigy Pharmaceuticals, Summit, New Jersey 07901 [Y. L.J ABSTRACT in 94 of 129 castrated men with metastatic prostatic carcinoma treated with aminoglutethimide plus hydrocortisone. Monthly serum dehydroepiandrosterone sulfate, androstenedione, tes tosterone, dihydrotestosterone, and free testosterone levels were mea sured in 94 of 129 patients with castration resistant prostatic carcinoma MATERIALS AND METHODS treated on a clinical protocol with aminoglutethimide (1000 mg/day) plus hydrocortisone (40 mg/day) Base-line steroid levels were not found to be Study Group and Clinical Trial Design. The Aminoglutethimide Study age related. Therapy reduced the median levels of all monitored steroids Group (Appendix A) is composed of IS institutions who instituted a but this suppression was not uniform. Although 87% of dehydroepian Phase II clinical trial in 1983 to determine whether therapy with AGT drosterone sulfate levels were suppressed compared to base-line meas plus HC had significant clinical activity in previously castrated men urements, only 52% of androstenedione and 49% of testosterone levels with progressive, évaluable,ormeasurable, prostatic carcinoma. Addi were reduced. Androstenedione levels in 34% of patients actually rose to tional eligibility criteria included normal hematopoietic, renal, and greater than twice base-line levels with similar but less frequent rises hepatic function, histologically documented prostatic carcinoma, in seen in testosterone, free testosterone, and dihydrotestosterone levels. formed written consent, and a life expectancy in excess of 3 months. The highest testosterone level measured was 190 ng/ml. Neither the Therapy consisted of AGT at a dose of 250 mg p.o. twice a day for cause, the deviation, nor the clinical significance of the androgen rise 2 weeks with the dose then escalated to 250 mg four times a day. seen in these patients was established. Therapy with aminoglutethimide Hydrocortisone was concurrently administered p.o. at an initial total plus hydrocortisone as administered in this study may not uniformly daily dose of 100 mg with the dose then reduced to a maintenance dose achieve the objective of suppressing adrenal androgen production. of 40 mg/day after 2 weeks of therapy. All patients were initially treated for 3 months unless frank disease progression occurred. At the end of 3 months, measurable or évaluablediseaseparameters were reassessed INTRODUCTION and a response determination was made by using National Prostate Cancer Project criteria (12). Patients who achieved disease regression The suppression or elimination of testicular androgen pro (partial or complete) or disease stabilization were continued on AGT duction is the only proven effective systemic therapy for meta- plus HC therapy until disease progression was documented. Patients static prostatic carcinoma (1). Endocrine induced remissions with disease progression had their therapy discontinued and were persist for an average of less than 2 years and median survival removed from study. from the date of subsequent relapse is only 6 months (2). Adrenal Steroid Levels. Serum samples were collected on all patients Adrenal steroid production is also a source of androgen pro prior to initiation of therapy and 4, 8, and 12 weeks later with the study design calling for the blood sampling to be performed at approximately duction and is not affected by most primary therapies directed the same time each morning. Serum was stored frozen at -20°C.Assays toward the testes (3). Consequently, adrenal suppression has for levels of DHEA-S, AND, testosterone, DHT, and FT were carried become a proposed method of second line hormonal therapy in out at Nichols Institute Laboratories in San Juan Capistrano, CA. prostate cancer (4). DHEA-S levels were quantified by a direct RIA with the lower limit Although surgical adrenalectomy in patients with prostatic of sensitivity being 5 /¿g/dl.Separate RIAs were also used to measure carcinoma progressing after castration leads to a more complete levels of AND, DHT, and testosterone levels. The lower limits of reduction in serum androgen levels (5), the significant morbidity sensitivity for these assays were 6 ng/dl for AND, 3 ng/dl for DHT, and mortality risk of this major surgical procedure has pre and 1 ng/dl for testosterone. FT was quantified after equilibrium cluded its routine application (6). AGT3 is an aromatase inhib dialysis with a lower limit of sensitivity of 1.2 pg/ml. itor and a potent inhibitor of adrenal corticosteroid synthesis Statistical Methodology. Timed steroid levels for the entire popula (7). Although all the effects of aminoglutethimide on the com tion and subpopulations were recorded as means and medians. A two- plex metabolic pathways in the adrenals have not been deline sided Wilcoxon signed rank test adjusted for ties and zeroes was applied to determine the significance of any change in median steroid levels ated, a major site of action is in the cortex where the conversion over time (13). A relationship between clinical variables and steroid of cholesterol to pregnenolone is inhibited (8). levels was assessed by linear regression analyses (14). A \2 table was Studies conducted primarily in women with breast carcinoma used to determine the significance of relationships between therapy have demonstrated that this drug can suppress some adrenal response rates and rising or falling adrenal steroid levels (15). steroid levels (9). However, uncertainty exists over whether aminoglutethimide can significantly inhibit the production of RESULTS androgenic steroids by the adrenal cortex (10, 11). We report herein the results of serial serum adrenal steroid measurements Clinical Results. Detailed results from the clinical trial are reported elsewhere." In brief, 129 patients were enrolled and 86 Received 5/19/86; revised 5/7/87; accepted 6/2/87. The costs of publication of this article were defrayed in part by the payment (67%) were évaluablefor response. Using National Prostate of page charges. This article must therefore be hereby marked advertisement in Cancer Project response criteria, partial tumor regressions were accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1Supported by a grant from Ciba-Geigy Pharmaceuticals. seen in 11 patients (13%). Stable disease criteria were docu 2To whom requests for reprints should be addressed, at Section of Hematology mented in 41 patients (48%), and frank disease progression was and Oncology, 111-D, Tucson VA Medical Center, Tucson, AZ 85723. 3The abbreviations used are: AGT, Aminoglutethimide; HC, hydrocortisone; 4 D. Crawford, F. R. Ahmann, W. Kreis, M. A. Davis, Y. J. Levasseur, and DHEA-S, dehydroepiandrosterone sulfate; AND, androstenedione; DHT, dihy- the Aminoglutethimide Study Group. Aminoglutethimide and hydrocortisone in drotestosterone; FT, free testosterone; RIA, radioimmunoassay; ACTH, adreno- the treatment of hormone refractory advanced adenocarcinoma of the prostate, corticotropic hormone. submitted to J. Clin. Oncol., 1986. 4736 Downloaded from cancerres.aacrjournals.org on September 23, 2021. © 1987 American Association for Cancer Research. ACT AND ADRENAL STEROID LEVELS documented in 34 patients (39%). Overall mean survival for the 50 entire study group was 13.3 ±9.3 (SD) months. Mean survival for partial responders was 20.1 ±8.1 months in comparison to 40 17.1 ±8.8 months for patients with stable disease and 10.5 ± 6.8 months for patients not responding to ACT plus HC. Therapy was well tolerated with toxicities including lethargy 30 (16%), rash (9%), nausea (12%), and edema (18%). Clinical findings of adrenal insufficiency were documented in four cases mcg/dl (5%). 20 Adrenal Steroid Levels. Of the 129 patients enrolled on study, a complete serum steroid level profile of 4 samples was obtained in 69 (53%) and a base-line and at least one follow-up study 10 after 2 months or more of ACT plus HC therapy was obtained X « in 94 (73%) of study entrants. Fig. \A displays a linear regres sion of base-line testosterone and Fig. IB displays base-line \14 i12 01 8Time AND levels as a function of age in these castrated men. The (weeks)— slopes of the generated lines for these adrenal androgens were Fig. 2. Serial median DHEA-S levels with 95% confidence limits in 69 patients not significantly different from zero. Hence, in these castrated treated with ACT plus HC for at least 3 months. A 80r- «— •oO)3OÕ1a0SiI72645648403224168 .. • «V— ' * •••*••••• ',*,*•-.*. 1 ' »* .i •\il»ì».~t•*?:» i L_± «-i* "i . i * Time (weeks) 0•'!•_ 35 41 47 53 59 65 71 77 83 89 Fig. 3. Serial median AND levels with 95% confidence limits in 64 patients treated for at least 3 months with ACT plus HC. Age at Entry (years) men, adrenal production of these androgens showed no trend B 20 to decline with age. Figs. 2 and 3 display serial median DHEA-S and AND levels, 18 respectively, from the 69 patients in whom a complete, 3-month 16 steroid level profile was obtained. Using a two-sided Wilcoxon signed rank test adjusted for ties and zeroes, the fall in the 14 median DHEA-S level was significant with P < 0.001, whereas the change in median AND levels was not significantly altered 12 by our therapy. The suppression of median base-line testoster o one, DHT, and FT levels were 9 ng/dl, 6.0 ng/dl, and 0.8 pg/ 10 ml, respectively, with values after 12 weeks of therapy falling I to median levels of 6.5 ng/dl, 5.0 ng/dl, and 0.7 pg/dl.
Load more

Recommended publications
  • The Adrenal Androgen Precursors DHEA and Androstenedione (A4)
    PERIPHERAL METABOLISM OF THE ADRENAL STEROID 11Β- HYDROXYANDROSTENEDIONE YIELDS THE POTENT ANDROGENS 11KETO- TESTOSTERONE AND 11KETO-DIHYDROTESTOSTERONE Elzette Pretorius1, Donita J Africander1, Maré Vlok2, Meghan S Perkins1, Jonathan Quanson1 and Karl-Heinz Storbeck1 1University of Stellenbosch, Department of Biochemistry, Stellenbosch, South Africa 2University of Stellenbosch, Mass Spectrometry Unit, Stellenbosch, South Africa The adrenal androgen precursors DHEA and androstenedione (A4) play an important role in the development and progression of castration resistant prostate cancer (CRPC) as they are converted to dihydrotestosterone (DHT) by steroidogenic enzymes expressed in CRPC tissue. We have recently shown that the adrenal C19 steroid 11β-hydroxyandrostenedione (11OHA4) serves as a precursor to the androgens, 11-ketotestosterone (11KT) and 11-keto-5α-dihydrotestosterone (11KDHT), and that the latter two steroids could play a role in CRPC. The aim of this study was therefore to characterise 11KT and 11KDHT in terms of their androgenic activity. Competitive whole cell binding assays revealed that 11KT and 11KDHT bind to the human androgen receptor (AR) with affinities similar to that of testosterone (T) and DHT. Transactivation assays on a synthetic androgen response element (ARE) demonstrated that the potencies and efficacies of 11KT and 11KDHT are comparable to that of T and DHT, respectively. Moreover, we show that both 11KT and 11KDHT induce the expression of AR-regulated genes (KLK3, TMPRSS2 and FKBP5) and cellular proliferation in the androgen dependent prostate cancer cell lines, LNCaP and VCaP. In most cases, 11KT and 11KDHT upregulated AR-regulated gene expression and increased LNCaP cell growth to a significantly higher extent than T and DHT. Mass spectrometry-based proteomics revealed that 11KT and 11KDHT, like T and DHT, results in the upregulation of multiple AR-regulated proteins in VCaP cells, with 11KDHT regulating more AR-regulated proteins than DHT.
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]
  • DHEA Sulfate, and Aging: Contribution of the Dheage Study to a Sociobiomedical Issue
    Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue Etienne-Emile Baulieua,b, Guy Thomasc, Sylvie Legraind, Najiba Lahloue, Marc Rogere, Brigitte Debuiref, Veronique Faucounaug, Laurence Girardh, Marie-Pierre Hervyi, Florence Latourj, Marie-Ce´ line Leaudk, Amina Mokranel, He´ le` ne Pitti-Ferrandim, Christophe Trivallef, Olivier de Lacharrie` ren, Stephanie Nouveaun, Brigitte Rakoto-Arisono, Jean-Claude Souberbiellep, Jocelyne Raisonq, Yves Le Boucr, Agathe Raynaudr, Xavier Girerdq, and Franc¸oise Foretteg,j aInstitut National de la Sante´et de la Recherche Me´dicale Unit 488 and Colle`ge de France, 94276 Le Kremlin-Biceˆtre, France; cInstitut National de la Sante´et de la Recherche Me´dicale Unit 444, Hoˆpital Saint-Antoine, 75012 Paris, France; dHoˆpital Bichat, 75877 Paris, France; eHoˆpital Saint-Vincent de Paul, 75014 Paris, France; fHoˆpital Paul Brousse, 94804 Villejuif, France; gFondation Nationale de Ge´rontologie, 75016 Paris, France; hHoˆpital Charles Foix, 94205 Ivry, France; iHoˆpital de Biceˆtre, 94275 Biceˆtre, France; jHoˆpital Broca, 75013 Paris, France; kCentre Jack-Senet, 75015 Paris, France; lHoˆpital Sainte-Perine, 75016 Paris, France; mObservatoire de l’Age, 75017 Paris, France; nL’Ore´al, 92583 Clichy, France; oInstitut de Sexologie, 75116 Paris, France; pHoˆpital Necker, 75015 Paris, France; qHoˆpital Broussais, 75014 Paris, France; and rHoˆpital Trousseau, 75012 Paris, France Contributed by Etienne-Emile Baulieu, December 23, 1999 The secretion and the blood levels of the adrenal steroid dehydro- number of consumers. Extravagant publicity based on fantasy epiandrosterone (DHEA) and its sulfate ester (DHEAS) decrease pro- (‘‘fountain of youth,’’ ‘‘miracle pill’’) or pseudoscientific asser- foundly with age, and the question is posed whether administration tion (‘‘mother hormone,’’ ‘‘antidote for aging’’) has led to of the steroid to compensate for the decline counteracts defects unfounded radical assertions, from superactivity (‘‘keep young,’’ associated with aging.
    [Show full text]
  • Role of Transport Systems in Cortisol Release from Human Adrenal Cells
    Role of transport systems in cortisol release from human adrenal cells Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultäten der Georg-August-Universität zu Göttingen vorgelegt von Abdul Rahman Asif aus Gujrat, Pakistan Göttingen 2004 D7 Referent: Prof. Dr. R. Hardeland Korreferent: Prof. Dr. D. Gradmann Tag der mündlichen Prüfung: To My parents & in loving memory of my grandma! She could not wait! CONTENTS I ABSTRACT ................................................................................................... IV LIST OF ABBREVIATIONS .......................................................................... VI 1 INTRODUCTION........................................................................................1 1.1 THE ADRENAL GLAND ANATOMY ...............................................................................................1 1.2 ADRENAL GLAND HORMONES....................................................................................................2 1.2.1 Biosynthesis of the steroid hormones...........................................................................................2 1.2.2 Regulation of adrenal glands........................................................................................................6 1.2.3 Actions of adrenal steroids ...........................................................................................................7 1.3 HUMAN ADRENOCORTICAL CELLS ............................................................................................8
    [Show full text]
  • Dehydroepiandrosterone: a Potential Therapeutic Agent in the Treatment
    Bentley et al. Burns & Trauma (2019) 7:26 https://doi.org/10.1186/s41038-019-0158-z REVIEW Open Access Dehydroepiandrosterone: a potential therapeutic agent in the treatment and rehabilitation of the traumatically injured patient Conor Bentley1,2,3* , Jon Hazeldine1,3, Carolyn Greig2,4, Janet Lord1,3,4 and Mark Foster1,5 Abstract Severe injuries are the major cause of death in those aged under 40, mainly due to road traffic collisions. Endocrine, metabolic and immune pathways respond to limit the tissue damage sustained and initiate wound healing, repair and regeneration mechanisms. However, depending on age and sex, the response to injury and patient prognosis differ significantly. Glucocorticoids are catabolic and immunosuppressive and are produced as part of the stress response to injury leading to an intra-adrenal shift in steroid biosynthesis at the expense of the anabolic and immune enhancing steroid hormone dehydroepiandrosterone (DHEA) and its sulphated metabolite dehydroepiandrosterone sulphate (DHEAS). The balance of these steroids after injury appears to influence outcomes in injured humans, with high cortisol: DHEAS ratio associated with increased morbidity and mortality. Animal models of trauma, sepsis, wound healing, neuroprotection and burns have all shown a reduction in pro- inflammatory cytokines, improved survival and increased resistance to pathological challenges with DHEA supplementation. Human supplementation studies, which have focused on post-menopausal females, older adults, or adrenal insufficiency have shown that restoring the cortisol: DHEAS ratio improves wound healing, mood, bone remodelling and psychological well-being. Currently, there are no DHEA or DHEAS supplementation studies in trauma patients, but we review here the evidence for this potential therapeutic agent in the treatment and rehabilitation of the severely injured patient.
    [Show full text]
  • Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues
    Author Manuscript Published OnlineFirst on July 21, 2017; DOI: 10.1158/1078-0432.CCR-17-1313 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Title: Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues Authors: Charles Dai1,2, Yoon-Mi Chung2, Evan Kovac2,4, Ziqi Zhu2, Jianneng Li2, Cristina Magi- Galluzzi3, Andrew J. Stephenson4, Eric A. Klein1,4, Nima Sharifi1,2,4,5 Author Affiliations: 1Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA 44195 2Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA 44195 3R.T. Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA 44195 4Department of Urology, Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH, USA 44195 5Department of Hematology & Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA 44195 Evan Kovac is currently affiliated with Montefiore Medical Center and the Albert Einstein College of Medicine, New York, NY, USA Running title: Adrenal-derived DHT biosynthesis in prostatectomy tissues Keywords: androgen metabolism, localized prostate cancer, 5α-reductase, adrenal steroids, prostatectomy Additional information: Financial support: This work was supported by funding from the Howard Hughes Medical Institute Medical Fellows Program (to CD), a Howard Hughes Medical Institute Physician-Scientist Early Career Award (to NS), a Prostate Cancer Foundation Challenge Award (to NS) and National Cancer Institute grants (R01CA168899, R01CA172382, and R01CA190289) to NS. Page 1 Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 21, 2017; DOI: 10.1158/1078-0432.CCR-17-1313 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Puberty in a Case with Novel 17-Hydroxylase Mutation and The
    European Journal of Endocrinology (2009) 160 325–330 ISSN 0804-4643 CASE REPORT Puberty in a case with novel 17-hydroxylase mutation and the putative role of estrogen in development of pubic hair Serap Turan, Abdullah Bereket, Tulay Guran, Teoman Akcay, Mahboubeh Papari-Zareei1 and Richard J Auchus1 Division of Pediatric Endocrinology, Department of Pediatrics, Marmara University, Altunizade, Uskudar, 34660 Istanbul, Turkey and 1Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8857, USA (Correspondence should be addressed to S Turan; Email: [email protected]) Abstract Objective: 17-Hydroxylase/17,20-lyase deficiency (17OHD) results from mutations in the CYP17A1 gene, leading to failure to synthesize cortisol, adrenal androgens, and gonadal steroids. Adrenarche is a consequence of the increased production of adrenal androgens. Here, we report a case carrying novel R239Q mutation causing complete functional loss of CYP17A1, and thus absence of adrenal and gonadal sex hormone production. The patient has had unexpected pubic hair development and insufficient breast development with estrogen replacement therapy. Possible mechanisms leading to pubic hair development and breast underdevelopment are discussed. Patient and methods: A 15-year-old female born to consanguineous parents presented with the lack of full breast development and irregular menses after the age of 14 years. She had Tanner III breast development on one side, Tanner I on the other side and Tanner I pubic hair and, no axillary hair development. The serum levels of FSH, LH, and progesterone were high and, estradiol was low. The measurement of basal and ACTH-stimulated steroids was consistent with the diagnosis of 17OHD.
    [Show full text]
  • STEROID PROFILES in the DIAGNOSIS of CANINE ADRENAL DISORDERS Jack W
    STEROID PROFILES IN THE DIAGNOSIS OF CANINE ADRENAL DISORDERS Jack W. Oliver, DVM, Ph.D Knoxville, TN INTRODUCTION Diagnosis of adrenal disease in domestic animals usually is dependent on the manipulation of the hypothalamo-pituitary-adrenal axis (HPA) and the measurement of cortisol (i.e., ACTH stim test; low dose dexamethasone suppression (LDDS) test; urine cortisol/creatinine ratio test; or the combined dexamethasone suppression/ACTH stimulation test). More recently, other steroid measurements have been utilized to evaluate the HPA, including steroid hormone profiles1,2, and 17-hydroxyprogesterone,3-5 which have revealed that suspected adrenal disease conditions may be caused by steroids other than cortisol (or in addition to cortisol).3 Determination of pituitary-dependent hyperadrenocorticism (PDH), or adrenal-dependent hyperadrenocorticism (ADH), is now usually made by evaluation of the 4-hour timepoint of the LDDS test6, by endogenous ACTH measurement,7 or by ultrasound visualization of the adrenal glands.7,8 Hyperadrenocorticism (HAC) is defined as an overproduction of steroid hormones by the adrenal cortex.4 Cushing’s syndrome refers to all causes of hyperadrenocorticism with excess production of cortisol,6 while atypical Cushing’s disease refers to hyperadrenocorticism caused by increased levels of intermediate adrenal steroids that frequently are referred to as “sex steroids”.9 STEROID HORMONE PROFILES/GENERAL Steroid hormone profiling in veterinary medicine was begun at The University of Tennessee Clinical Endocrinology Service, with the premise being that multiple steroid hormone analyses would increase the diagnostic accuracy of adrenal function tests.1 Measurement of multiple steroids in Pomeranians2 led to the recognition of a syndrome called “Alopecia-X”11 by dermatologists.
    [Show full text]
  • Dehydroepiandrosterone: Biological Effects and Clinical Significance
    Reprinted with written permission from Alternative Medicine Review, Vol. 1, #2, 1996, pp. 60-69, Thorne Research, Inc. Dehydroepiandrosterone: Biological Effects and Clinical Significance Alan R. Gaby, M.D. Abstract Dehydroepiandrosterone (DHEA) is a steroid hormone secreted in greater quan- tity by the adrenal glands than any other adrenal steroid. For many years, scientists assumed that DHEA merely functioned as a reservoir upon which the body could draw to produce other hormones, such as estrogen and testosterone. However, the recent identification of DHEA receptors in the liver, kidney and testes of rats strongly suggests that DHEA may have specific physiologic actions of its own. Circulating levels of DHEA decline progressively with age; this age-related decline does not occur with any of the other adrenal steroids. Epidemiologic evidence indicates that higher DHEA levels are associated with increased longevity and prevention of heart disease and cancer, sug- gesting that some of the manifestations of aging may be caused by DHEA deficiency. Animal and laboratory data indicate that administration of DHEA may prevent obesity, diabetes, cancer (breast, colon and liver), and heart disease; enhance the functioning of the immune system; and prolong life. In humans, evidence exists that DHEA might be associated with autoimmune diseases such as lupus, rheumatoid arthritis and mul- tiple sclerosis; chronic fatigue syndrome; acquired immunodeficiency syndrome (AIDS); allergic disorders; osteoporosis; and Alzheimer’s disease. Although administration of DHEA appears to be safe, its long-term effects are unknown, and it is possible that adverse consequences will become evident with chronic use. It is therefore important that this hormone be used with care and that practitioners err on the side of caution when contemplating DHEA supplementation.
    [Show full text]
  • Physiological and Biochemical Aspects of 17Β-Hydroxysteroid Dehydrogenase Type 2 and 3
    Physiological and Biochemical Aspects of 17β-Hydroxysteroid Dehydrogenase Type 2 and 3 Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Roger Thomas Engeli aus Sulgen (TG), Schweiz Basel, 2017 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung-Nicht kommerziell 4.0 International Lizenz. Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Alex Odermatt und Prof. Dr. Rik Eggen Basel, den 20.06.2017 ________________________ Dekan Prof. Dr. Martin Spiess 2 Table of Contents Table of Contents ............................................................................................................................... 3 Abbreviations ..................................................................................................................................... 4 1. Summary ........................................................................................................................................ 6 2. Introduction ................................................................................................................................... 8 2.1 Steroid Hormones ............................................................................................................................... 8 2.2 Human Steroidogenesis....................................................................................................................
    [Show full text]
  • 11-Keto-Testosterone and Other Androgens of Adrenal Origin
    Physiol. Res. 69 (Suppl. 2): S187-S192, 2020 https://doi.org/10.33549/physiolres.934516 REVIEW 11-Keto-testosterone and Other Androgens of Adrenal Origin Luboslav STÁRKA, Michaela DUŠKOVÁ, Jana VÍTKŮ 1Institute of Endocrinology, Prague, Czech Republic Received February 20, 2020 Accepted April 14, 2020 Summary half in the adrenals. The androgenic potential of these The adrenal glands produce significant amounts of steroid steroids is low. However, the human adrenal also secretes hormones and their metabolites, with various levels of 11-oxygenated androgens (11-oxy-androgens), including androgenic activities. Until recently, the androgenic potency of 11β-hydroxy-androstenedione. Plasma levels of these adrenal-derived compounds were not well known, but 11β-hydroxy-androstenedione (means ± SD) in healthy some recent studies have shown that the production of 11-oxo- persons in the morning are 8.69±2.88 (men), 7.72±2.85 and 11β-hydroxy-derived testosterone and dihydrotestosterone (women), 8.73±5.13 (boys) and 7.88±5.23 (girls) nmol/l, evidently have high androgenic activity. This fact has clinical respectively. The concentrations of these hormones importance, for instance, in various types of congenital adrenal follow the circadian rhythm pattern of cortisol, increasing hyperplasia with androgenization or polycystic ovarian syndrome, markedly after corticotropin stimulation and suppressed and laboratory determinations of these substances could help to by dexamethasone (Putz et al. 1987). 11β-hydroxy- better evaluate the total androgen pressure in patients with these androstenedione serves as the precursor of several highly disorders. Another area of concern is the treatment of prostate potent androgens, the 11-oxygenated derivatives of cancer with androgen deprivation, which loses effectiveness testosterone and dihydrotestosterone.
    [Show full text]
  • The Effects of ACTH on Steroid Metabolomic Profiles in Human
    327 The effects of ACTH on steroid metabolomic profiles in human adrenal cells Yewei Xing, Michael A Edwards, Clarence Ahlem1, Mike Kennedy1, Anthony Cohen, Celso E Gomez-Sanchez2 and William E Rainey Department of Physiology and Surgery, Georgia Health University, 1120 15th Street, Augusta, Georgia 30912, USA 1Hollis-Eden Pharmaceuticals, Inc., San Diego, California 921222, USA 2University of Mississippi Medical Center, Jackson, Mississippi 39126, USA (Correspondence should be addressed to W E Rainey; Email: [email protected]) Abstract The adrenal glands are the primary source of mineralocorti- ACTH treatment (48 h). Cortisol production responded the coids, glucocorticoids, and the so-called adrenal androgens. most to ACTH treatment, with a 64-fold increase. Under physiological conditions, cortisol and adrenal andro- Interestingly, the production of two androgens, androstene- gen synthesis are controlled primarily by ACTH. Although it dione and 11b-hydroxyandrostenedione (11OHA), that were is well established that ACTH can stimulate steroidogenesis in also produced in large amounts under basal conditions the human adrenal gland, the effect of ACTH on overall significantly increased after ACTH incubation. In H295R production of different classes of steroid hormones has not cells, 11-deoxycortisol and androstenedione were the major been defined. In this study, we examined the effect of products under basal conditions. Treatment with forskolin ACTH on the production of 23 steroid hormones in adult increased the percentage of 11b-hydroxylated products, adrenal primary cultures and 20 steroids in the adrenal cell including cortisol and 11OHA. This study illustrates that line, H295R. Liquid chromatography/tandem mass spec- adrenal cells respond to ACTH through the secretion of a trometry analysis revealed that, in primary adrenal cell variety of steroid hormones, thus supporting the role of cultures, cortisol and corticosterone were the two most adrenal cells as a source of both corticosteroids and androgens.
    [Show full text]